Menu Search
Equities

Pacific Edge Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PEB:ASX

Pacific Edge Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.19
  • Today's Change-0.01 / -5.00%
  • Shares traded74.19k
  • 1 Year change+265.38%
  • Beta0.8003
Data delayed at least 20 minutes, as of Feb 16 2026 03:47 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Pacific Edge Limited is a global cancer diagnostics company. The Company is engaged in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. The Company operates through two segments: Commercial and Research. The Commercial segment is engaged in the sales, marketing, laboratory, and support operations to run the commercial businesses worldwide. The Research segment is engaged in the research and development of diagnostic and prognostic products for human cancer. The Company provides its suite of Cxbladder tests globally through its wholly owned laboratories in New Zealand and the United States. Its Cxbladder tests assist clinicians to safely de-intensify hematuria evaluation from low incidence populations; resolve diagnostic dilemmas and monitor patients for the recurrence of urothelial carcinoma. It operates in New Zealand, Australia, Singapore, and the United States.

  • Revenue in NZD (TTM)16.83m
  • Net income in NZD-34.55m
  • Incorporated2001
  • Employees0.00
  • Location
    Pacific Edge LtdCentre for Innovation, 87 St David St,PO Box 56DUNEDIN 9016New ZealandNZL
  • Phone+64 35776733
  • Fax+64 39749393
  • Websitehttps://www.pacificedgedx.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.